Objective: Syndecans are reported to have variable expression in several solid tumors and blood cancers. The cause provoking altered expression of syndecans is not known to date. We studied copy number status of syndecan1 (SDC1) and significance of SDC1 gene product (syndecan1, SDC1) expression in cervical cancers. Methods: Using 121 cases of cervical cancer tissues, we screened SDC1 expression pattern using immunohistochemistry. We analyzed the relationship between SDC1 expression and clinicopathological parameters. To find possible causes of the expression change, we exploited interphase fluorescent in situ hybridization to screen copy number alteration of SDC1. Results: Among 121 cases, 101 (83.5%) were positive and 20 (16.4%) were negative for SDC1. Among the parameters, age, histological type, and grade were significantly associated with SDC1 expression (p<0.05). Strong SDC1 expression in the cytoplasm showed better patient survival (p=0.02). In multivariate regression model, grade and SDC1 expression were independent prognostic factors (p<0.05). SDC1 in cervical cancers did not show copy number alteration. Conclusion: Strong SDC1 expression in the cytoplasm of tumor cells predicts better patient survival. The change of SDC1 expression in cervical cancers is not caused by copy number alteration of the gene.
INTRODUCTION
With the help of effective screening and treatment methods, mortality of cervical cancer has been greatly reduced. How ever, cervical cancer still is the second leading cause of cancer deaths in women worldwide [1] . The single most important factor in cervical oncogenesis is high oncogenic risk human pa pillomaviruses (HPVs). HPVs interfere with Rb and p53 fun c tion to make cervical epithelial cells cancerprone state. How ever, only a small portion of HPVinfected patients de velop cer vical cancer and this necessitates further studies of other factors, including cancerrelated genes at the molecular level. Among the genes studied so far, fibroblast growth factor re cep tor (FGFR) is found constitutively activated [2] . Since the introduction of genomewide, highthroughput research modalities, many studies to find diseasespecific markers were conducted. As a result, they proposed several genes or gene products to have prognostic significance. Among the targets, significance of syndecans is reported in a few solid tumors and blood cancers.
Syndecans are plasma membrane proteoglycans and their cytoplasmic domain is thought to interact with the actin cyto skeleton [3] . They act as coreceptors by binding fibroblast growth factors (FGFs) and presenting them to FGFRs [3] . There are 4 different kinds of syndecans in vertebrates [4] . Among syndecans, which are expressed in various types of cells, synde can1 (SDC1) is expressed in epithelia and plasma cells [5] .
Several studies on the relationship between syndecan ex [6] , hepato cellular carcinoma [7] , mesothelioma [8] , and lung cancer [9] , were decreased. However, in some malignant tumors, such as endometrial cancer [10] , ovarian cancer [11] and pancreatic can cer [12] , SDC1 expression is increased. Those studies repor ted quantitative changes of SDC1 expression and the nature of the changes is dependent on the organ that the tumor has occurred. The syndecan family of matrix receptors is known to involve integrin (β4)dependent signaling in human squa mous carcinoma cells [13] . Prognostic significance of SDC1 expression is evaluated in several human cancers. Gallbladder cancer with SDC1 ex pre ssion showed more frequent lymph node metastasis [14] .
In this study, we compared SDC1 expression with several pa tho logic parameters in cervical cancers to find any significant association. To find possible cause of changes in SDC1 expre ssion, we measured copy numbers of SDC1 in cervical cancers using fluorescent in situ hybridization (FISH). 
MATERIALS AND METHODS

Patients and tumor samples
Immunohistochemistry
Sections from TMA blocks were transferred to ProbeOn Plus slides (Fisher Scientific, Pittsburgh, PA, USA) and incubated for two hours in 56 o C chamber (Agilent Technologies, Santa Clara, CA, USA). The sections were deparaffinized in xylene 3 times and re hydrated through 100%, 90%, 80%, 70% ethanol and Trisbuff ered saline (TBS, pH 7.4). For antigen retrieval, the ti ssues were im mersed in 10 mM sodium citrate buffer (pH 6.0) and boiled in a microwave for 20 
Fluorescent FISH
To synthesize SDC1 FISH probe, we used BioPrime Array CGH Genomic Labeling Module (Invitrogen, Carlsbad, CA, USA). BAC clone (PRP11202B22; Invitrogen) was used as template and Spectrum OrangedUTP (Abbott Molecular, Abbott Park, IL, USA) was used to label the probe. Aquarius Satellite probe of chro mo some 2 (Cytocell, Cambridge, UK) was purchased as the reference probe. Location of homemade SDC1 probe was confirmed in metaphase spread of normal peripheral mo no nuclear cells. Tissue processing and hybridization was done using Paraffin Pretreatment Kit I (Abbott Molecular) and Ther moBrite (Abbott Molecular). We followed the manu facturer' s recommended FISH protocols. We counted the num ber of fluorescent spots in at least 100 nuclei in each case.
Statistical analysis
Chisquare test and Fisherexact test was used to evaluate sig ni ficance of SDC1 expression in terms of pathologic fea tures. The numbers of target spots and reference spots in FISH were compared using the chisquare test. For survival analysis, KaplanMeier method was used. To test the difference be tween survival curves of different groups, we used the non pa ra me t ric logrank test. We used Cox's multivariate pro portional ha zard model to determine the prognostic values of selected cli ni co pathologic parameters. We used R ver. 2.10 (R foundation, Vienna, Austria) for statistical cal culations and pro duction of graphs. (Fig. 1) . We com pared the status of cytoplasmic SDC1 expression and some patholo gic parameters. SDC1 was more frequently expressed in squ a mous cell carcinomas than adenocarcinomas and adeno squa mous carcinomas (p=0.001). High grade tumors had less percentage of SDC1 expression than low grade tu mors (p=0.036). We could not find any correlation between status of recurrence, lymph node metastasis, tumor stage and SDC1 expression (Table 1 ). Multivariate analysis showed that tumor grade and strong SDC1 expression were independent prognostic factors for survival ( Table 2 ).
Copy number status of SDC1
There was no significant difference between the numbers of target (SDC1) spots and references spots (p>0.05) in the cases showing increased SDC1 immunoreactivity (Fig. 2) .
Survival analysis
We analyzed patient survival among the groups with differ ent SDC1 expression. Difference between the group of strong SDC1 expression and other groups was statistically significant (p=0.0219) (Fig. 3) .
DISCUSSION
In this study, we showed that SDC1 expression is increased in cervical cancer and that most of the SDC1 accumulates in the cytoplasm of cancer cells. The finding that high grade tu mors show decreased expression of SDC1 is consistent with a 164 www.ejgo.org previous report [15] .
Silencing SDC1 expression causes reduced focal adhesion plaque formation and enhanced cell spreading and motility on collagen I substrates [16] . Considering the fact that spread ing and motility of cancer cells are highly related to invasion and distant metastasis, SDC1 positive tumors might have a more favorable biological behavior. This possible benefit of SDC1 may explain the findings that SDC1 expression is more co mmon in low grade tumors and that patients with strong SDC1 expression have more favorable outcome in survival analysis. We also showed that increased amounts of SDC1 is confined to the cytoplasm of tumor cells. Normal membranous distri bu tion of SDC1 vanished in the neoplastic cells. Due to trans po si tion of SDC1 from the cytoplasmic membrane to cytoplasm, the cells lose effective SDC1 on their surfaces. Considering the function of SDC1, these cells might lose con nection to the extracellular matrix and move more freely than normal cells. In creased mobility of the cells can contribute to invasion and metastasis. Alteration of SDC1 distribution may be caused by de gradation of the glycosaminoglycan chains, or expression of a mutated core protein that cannot undergo glycanation [17] .
In one report, an inverse correlation between the expression of SDC1 in the tumor and lymph node metastasis was sugge sted [18] . However, they failed to show statistical significance, as we did.
In other malignancies, such as endometrial cancers [19] and invasive ductal breast carcinomas [20] , SDC1 expression is reported to be associated with better prognosis. However cer tain malignancies, such as gallbladder cancer [14] and pros tate cancer [21] , it has been reported to have shorter survival time with positive SDC1 expression. This contradictory effect of SDC1 might be due to the difference of the site of origin that the tumors have come from. SDC1 can be detached from the cytoplasmic membrane and become soluble form. The soluble SDC1 is associated with shorter survival in chronic lymphocytic leukemia [22] and lung cancer [23] . SDC1 expression of the bone marrow environ ment is associated with shorter eventfree survival of multiple myeloma [24] . Adverse effect of SDC1 expression in tumor stroma has also been reported in oral carcinomas [25] and pancreatic cancer [26] . Decreased expression of SDC1 can be ascribed to increased degradation of the protein in cancer cells without any change in the gene expression. As a mechanism of decreased SDC1, decreased biosynthesis of the protein is suggested in gastric cancer [27] . Sometimes changes in copy number of a gene re sult in alterations in gene expression. To find a cause of SDC1 expression change, we screened the copy number of SDC1 and found no alteration in its copy number. It seems that al teration of SDC1 expression is caused by changes other than copy number alteration. The mechanism of SDC1 expression in malignant cell is not known to date. We found two reports claiming that SDC1 expression did not predict survival [28, 29] . In those articles, authors scored immunoreactivity of SDC1 on the surface of cells. SDC1 can be found on the surface of normal epithelial cells, and cervi cal cancer cells may retain SDC1 expression on the surface. Because we focused on abnormal location of SDC1 in tumor cells, we scored cytoplasmic expression of SDC1. With this scoring scheme, we found that strong SDC1 expression was associated with better survival. This explains the difference of our results and previous reports.
In conclusion, we showed intense SDC1 expression is asso ciated with better prognosis in cervical cancer. Tumor grade and histological type is also related to the SDC1 expression. The alteration of SDC1 expression in cervical cancer is not caused by copy number changes of SDC1 in the tumor.
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